• English
  • Sign In
  • Contact Us
×
News & Blogs » Molecular Biology News » Advancing Cell Therapies for Duchene Muscular Dystrophy

Gene Synthesis & DNA Synthesis Services

Get Your Genes from the Top Gene Synthesis Provider

100% Sequence Accuracy Guaranteed

Learn More

Advancing Cell Therapies for Duchene Muscular Dystrophy

What is Duchene muscular dystrophy?

Duchene muscular dystrophy (DMD) is a rare neuromuscular disease caused by recessive mutations in the dystrophin gene that severely affect dystrophin protein expression and function. Different types of mutations in the dystrophin gene have been linked to DMD, including predominantly large deletions (i.e., involving one or more coding sequences), but also duplications, single nucleotide base changes, and small insertions/deletions (Duan et al. 2021).

Because the dystrophin gene is localized to the X-chromosome, females are generally asymptomatic carriers, and disease manifests almost exclusively in males, with a global prevalence of ~7 in 100,000 live male births (Crisafulli et al. 2020). In affected males, DMD disease’s onset occurs early and within the first 5 years of life, manifesting through motor difficulties (e.g., frequent falls). DMD is a progressive disease that results in increased skeletal muscle wasting; typically, 10-year-old patients are wheelchair-bound and rely on artificial respirators by 20 years of age. Additionally, since the functional muscle dystrophin isoform (Dp427m) is critical in cardiac muscle, patients develop cardiomyopathy by 10 years of age (Falzarano et al. 2015). Ultimately, DMD patients perish due to combined cardiac and respiratory failure at around 20-40 years of age.

Why is dystrophin so crucial for muscle function?

Dystrophin is a large 427 kDa intracellular protein that sits close to the plasma membrane of muscle cells, acting as a bridge between sarcolemmal and cytoskeletal proteins. Through several structural domains, dystrophin interacts directly with critical cytoskeletal (e.g., actin), transmembrane (e.g., beta-dystroglycan), and cytosolic (e.g., dystrobrevin) proteins. Additionally, dystrophin indirectly associates with proteins within all cellular compartments, including critical extracellular proteins such as alpha-dystroglycan (alpha-DG) and laminin-211 (Dowling et al. 2021).

Dystrophin Complexome:“The lower panel shows a model of the spatial configuration of the dystrophin complexome in skeletal muscle fibers. Shown is the dystrophin core complex consisting of the dystrophin isoform Dp427-M, dystroglycans (DG), sarcoglycans (SG), sarcospan (SSPN), syntrophins (SYN) and dystrobrevins (DYB), as well as the wider dystrophin-associated network that forms associations with the extracellular matrix, the sarcolemma, the cytoskeleton and the sarcomere. “Figure 1 lower panel, retrieved from (Dowling et al. 2021). https://creativecommons.org/licenses/by/4.0/

Through these protein interactions, dystrophin, as part of the dystrophin-associated glycoprotein complex (DGC), participates in various functions, such as cell signaling to sustain excitation-contraction coupling (EC coupling), cytoskeleton organization, muscle fiber stability, and lateral force transmission. Therefore, a lack of dystrophin expression and function leads to plasma membrane instability and several pathological changes in the muscle, including fiber degeneration, fibrosis, and chronic inflammation (Dowling et al. 2021).

A new cell therapy helping late-stage DMD patients

The progression of DMD disease is accelerated by inflammatory mechanisms, such as immune cell infiltration and concomitant increase in cytokines. Therefore, the go-to therapy to stave away DMD’s progress has been based on the use of steroids. Corticosteroids, such as Prednisone, have helped DMD patients improve muscle strength and function, and their long-term use provides cardiac and respiratory function benefits. Nevertheless, corticosteroid-based treatments are not without side effects, including metabolic, nervous systems, and gastrointestinal disturbances. Additionally, long-term corticosteroid treatments are not well tolerated by all patients, and some patients do not gain any clinical benefits (Falzarano et al. 2015).

A new progenitor cell-based approach to delaying the progression of DMD relies on the use of Cardiosphere-derived cells (CDCs). Cardiospheres comprise a heterogeneous cardiac cell population, including stem/progenitor cells, known to have regenerative potential. CDCs secrete a range of bioactive factors (e.g., non-coding RNA and microRNAs) effective in promoting angiogenesis and progenitor cell recruitment while suppressing cell death, fibrosis, and inflammation. Although these benefits were initially demonstrated in the context of heart disease, studies in a preclinical model of DMD, the mdx mouse, showed the value of CDCs to reverse cardiac and skeletal myopathy and concomitantly improve motor function. These findings were instrumental in driving the first clinical studies initiated in 2015 (HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne-NCT02485938). These first Phase 1/2 studies aimed to evaluate the safety and efficacy of intracoronary infused Allogeneic Cardiosphere-Derived Cells (CAP-1002) treatment in DMD patients with cardiomyopathy. Guided by positive preclinical findings, these studies assessed the effects of CAP-1002 treatment on cardiac and skeletal muscle and demonstrated improved functions in both (Taylor et al. 2019).

In 2018 a new Phase 2 study (HOPE-2) was initiated to evaluate the safety and efficacy of CAP-1002 therapy administered intravenously in improving motor, pulmonary and cardiac functions in non-ambulatory and ambulatory DMD patients (NCT03406780). Unlike the original HOPE clinical studies, in HOPE-2, investigators administered multiple doses of CAP-1002 (i.e., a total of 4 doses, infused every 3 months) and executed a double-blind, randomized, placebo-controlled trial. Recently, findings from these Phase 2 studies demonstrated that CAP-1002 treatment improved upper limb function and cardiac function in late-stage DMD patients relative to placebo (McDonald et al. 2022).

How much do you know about Duchene muscular dystrophy (DMD)?

Take the Quiz, test your DMD knowledge, and try your luck at some cool prizes.

  1. A. Transferrin
    B. Retinol-binding protein
    C. Dystrophin
  2. A. X-chromosome
    B. Y-chromosome
    C. Chromosome 11
  3. A. Insulin
    B. Prednisone
    C. Celebrex
  4. A. Coagulation
    B. Cardiac and Respiratory
    C. Digestive
  5. A. non-coding RNA and microRNA
    B. Calnexin
    C. Cytochrome C
  6. Name:

    Email:

    Organization:

    Would you like to receive resources and communications from GenScript?

    Yes
    No

    Which of the options below better matches your research projects. Please, select all that apply to your research interest.

    Gene synthesis, Cloning, and Plasmid Prep
    Oligo
    Gene Editing
    Peptide
    Recombinant Protein
    Antibody
    Cell Line
    Viral Vector Services (Lentivirus, AAV)
    Biological Services
    Lab Apparatus or Consumables

Terms and Conditions:

  • This campaign starts on April 28th at 12:00 A.M., 2022, and ends on May 19th at 11:59 A.M., 2022 EST.
  • Users who answer all Quiz questions successfully will be eligible to win a $20 Amazon gift card or 1000 GenScript points.
  • Users may take the Quiz several times but only have one chance to win a prize.
  • We will contact the winners within one month to arrange gift distribution.
  • GenScript reserves the right to the final explanation and details of this campaign. Contact us at [email protected] if you have further questions.

Reference


Crisafulli, S. et al. Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis. Orphanet Journal of Rare Diseases (2020) doi:10.1186/s13023-020-01430-8.

Dowling, P. et al. The dystrophin node as integrator of cytoskeletal organization, lateral force transmission, fiber stability and cellular signaling in skeletal muscle. Proteomes (2021) doi:10.3390/proteomes9010009.

Duan, D., Goemans, N., Takeda, S., Mercuri, E. & Aartsma-Rus, A. Duchenne muscular dystrophy. Nature Reviews Disease Primers (2021) doi:10.1038/s41572-021-00248-3.

Falzarano, M. S., Scotton, C., Passarelli, C. & Ferlini, A. Duchenne muscular dystrophy: From diagnosis to therapy. Molecules (2015) doi:10.3390/molecules201018168.

McDonald, M. C. et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2022) doi.org/10.1016/S0140-6736(22)00012-5.

Taylor, M. et al. Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. Neurology (2019) doi:10.1212/WNL.0000000000006950.

* We'll never share your email address with a third-party.

Latest News & Blogs